BRIEF-Cardiome Announces Expanded Label For Aggrastat In China

* CARDIOME ANNOUNCES EXPANDED LABEL FOR AGGRASTAT® IN CHINA INCLUDING NEW STEMI INDICATION AND HIGH DOSE BOLUS REGIMEN

* CARDIOME PHARMA - AGGRASTAT EXPANDED LABEL NOW INCLUDE PATIENTS WITH STEMI WHO ARE INTENDED FOR PRIMARY PERCUTANEOUS CORONARY INTERVENTION

* CARDIOME PHARMA - CHINESE CENTER FOR DRUG EVALUATION ALSO APPROVED AGGRASTAT HIGH DOSE BOLUS REGIMEN TO BE USED ON BOTH INDICATED PATIENT POPULATIONS IN STUDY Source text for Eikon: Further company coverage: